Nycomed to market Roche's osteoporosis treatment Bonviva in key Asia-Pacific markets
(Thomson Reuters ONE) -
Nycomed /
Nycomed to market Roche's osteoporosis treatment Bonviva in key Asia-Pacific
markets
. Processed and transmitted by Thomson Reuters ONE.
The issuer is solely responsible for the content of this announcement.
* Nycomed completes transfer of marketing authorisations from Roche in
multiple territories
* Licence transfers represent further strengthening of Nycomed's position in
Asia-Pacific through in-licensing of innovative brands
Nycomed today announced that it has completed the transfer of marketing
authorisation approvals in a number of key Asia-Pacific markets for osteoporosis
treatment Bonviva (Ibandronate). The licensing agreement with Roche (SIX: RO,
ROG; OTCQX: RHHBY) marks a further strengthening of Nycomed's bone health
franchise in the region.
The licensing and supply agreement includes China, Hong Kong, Malaysia,
Australia, New Zealand, Philippines, Singapore, Taiwan and Vietnam and a future
option to commercialise Bonviva in additional Asia-Pacific territories.
Under the terms of the deal, Nycomed will become marketing authorisation holder
in all the licensed territories. Bonviva is a bisphosphonate used in the
treatment of osteoporosis in postmenopausal women. Financial details of the
agreement were not disclosed.
Nycomed has one of the highest proportions of sales from emerging markets among
major pharmaceutical companies. The company recently opened offices in China,
South Korea, Indonesia, Malaysia and the Philippines, rapidly increasing its
capabilities through the repatriation of its own core brands and the licensing
of innovative products from other companies.
In November 2010 Nycomed made a major commitment to the Chinese market through
the acquisition of a majority stake in Guangdong Techpool Bio-Pharma, which
specialises in protein-based therapies.
Commenting on today's announcement Guido Oelkers, Executive Vice President,
Commercial Operations, said: "The in-licensing of Bonviva from Roche is another
important step towards Nycomed's expansion in the Asia-Pacific region and
demonstrates our growing attraction as a marketing partner for leading companies
and brands in these dynamic countries. Bonviva is a high quality product which
plays an important role in combating the impact of osteoporosis in post
menopausal women."
About Nycomed
Nycomed is a privately owned global pharmaceutical company with a diversified
portfolio focused on branded medicines in gastroenterology, respiratory and
inflammatory diseases, pain, osteoporosis and tissue management. A range of OTC
products completes the portfolio.
Its R&D is structured around collaborations. In-licensing and expanding in
emerging markets are cornerstones of the company's growth strategy.
Nycomed employs 12,500 associates worldwide, and its products are sold in more
than 100 countries. It has strong platforms in Europe and in fast-growing
markets such as Russia/CIS, Latin America, Asia and the Middle East. In the US
and Japan its products are available through best in class partners.
Headquartered in Zurich, Switzerland, the company generated total sales of
? 3.2 billion in 2010 and an adjusted EBITDA of ? 851 million.
For more information visitwww.nycomed.com
For further information
Media:
General phone: +41 44 555 15 10
Tobias Cottmann, phone: +41 44 555 15 01
Investors:
Christian B. Seidelin, phone: +41 44 555 11 04
This press release has been issued by Nycomed International Management GmbH,
Thurgauerstrasse 130, CH-8152 Glattpark-Opfikon, Zurich, Switzerland.
--- End of Message ---
Nycomed
Thurgauerstrasse 130 Glattpark-Opfikon Switzerland
Press Release Bonviva_EN:
http://hugin.info/144179/R/1523549/459562.pdf
Press Release Bonviva_DE:
http://hugin.info/144179/R/1523549/459563.pdf
This announcement is distributed by Thomson Reuters on behalf of
Thomson Reuters clients. The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and
other applicable laws; and
(ii) they are solely responsible for the content, accuracy and
originality of the information contained therein.
Source: Nycomed via Thomson Reuters ONE
[HUG#1523549]
Unternehmensinformation / Kurzprofil:
Datum: 15.06.2011 - 09:59 Uhr
Sprache: Deutsch
News-ID 55572
Anzahl Zeichen: 4871
contact information:
Town:
Glattpark-Opfikon
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 219 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Nycomed to market Roche's osteoporosis treatment Bonviva in key Asia-Pacific markets"
steht unter der journalistisch-redaktionellen Verantwortung von
Nycomed (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
